<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064881</url>
  </required_header>
  <id_info>
    <org_study_id>DMMET_LP001</org_study_id>
    <nct_id>NCT02064881</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Metformin Glycinate on Postprandial Lipemia</brief_title>
  <official_title>Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of metformin glycinate vs metformin
      hydrochloride on postprandial lipemia. 72 patients will be included, they will be randomized
      and assigned into one of the two treatment groups: metformin glycinate 1240 mg BID or
      metformin hydrochloride 1000 mg BID (36 patients per group). The patients will be followed
      for 4 months.

      Blood count, blood chemistry, liver profile, lipid profile, HbA1c, apolipoprotein B, oxidized
      LDL, fibroblast growth factor 21, leptin, adiponectin, C-reactive protein, free fatty acids,
      fibrinogen, Goodpasture Binding Protein (GPBP) and antioxidant activity of plasma will be
      measured at baseline and 4 months.

      Additionally, after a structured meal, the following parameters will be measured: glucose,
      insulin, triglycerides, apolipoprotein B and oxidized LDL. (baseline and 4 months).
      Throughout the study adverse events will be documented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective: To compare the effect of metformin glycinate with metformin hydrochloride
      postprandial lipemia (area under the curve of triglycerides)

      Study group

      Tablets of 620 mg of metformin glycinate. Scaling: 1 tablet at night for 3 days, followed by
      1 tablet in the morning and 1 tablet at night for 3 days, followed by 1 tablet in the morning
      and 2 tablets in the evening for 3 days and finally, 2 tablets in the morning and 2 tablets
      in the evening to complete the study. Final study dose 1240 mg every 12 hours.

      Comparative group

      500 mg tablets of metformin hydrochloride. Scaling: 1 tablet at night for 3 days, followed by
      1 tablet in the morning and 1 tablet at night for 3 days, followed by 1 tablet in the morning
      and 2 tablets in the evening for 3 days and finally, 2 tablets in the morning and 2 tablets
      in the evening to complete the study. Final study dose 1000 mg every 12 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial lipemia at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in oxidized LDL at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FGF-21 levels at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in A1C at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uric acid at 4 months</measure>
    <time_frame>baseline, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>metformin glycinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.
Total study dose: 1240mg every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.
Total study dose: 1000mg every 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin glycinate</intervention_name>
    <description>All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .</description>
    <arm_group_label>metformin glycinate</arm_group_label>
    <other_name>DMMET-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)</description>
    <arm_group_label>metformin hydrochloride</arm_group_label>
    <other_name>HCL MET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes

          -  Between 35 and 65 years old

          -  Patients with type 2 diabetes within two years of diagnosis according to the ADA
             criteria

          -  Overweight patients (BMI between 25.5 and 29.9 kg/m2) or with grade 1 obesity (BMI
             between 30.0 and 34.9 kg/m2), according to WHO classification

          -  Low HDL levels: &lt;50 in women and &lt;40 mg/dL in men

          -  Hypertriglyceridemia: &gt;150 and less than 300 mg/dL

          -  Patients who had not taken antidiabetes drug treatment or with diet and exercise
             treatment, or with metformin or DPP4 inhibitor monotherapy

          -  HbA1c between 6.5 and 8.5%.

          -  Creatinine clearance &gt;60 ml/min (calculated by Cockcroft and Gault)

          -  Informed consent form signed.

          -  Women using contraception.

        Exclusion Criteria:

          -  Patients with other types of diabetes (type 1, LADA, MODY, etc.).

          -  Patients with primary dyslipidemia.

          -  Patients with poorly substituted hypothyroidism TSH &gt; 5 mU/mL.

          -  Patients hospitalized in the last month.

          -  Patients with a disease of poor short-term prognosis

          -  Patients with autoimmune or rheumatic diseases.

          -  Patients with acute infection or febrile illness.

          -  History of chronic liver disease or ALT or AST ≥ 2.0 times the upper limit of normal,
             or GGT ≥ 3 times the upper limit of normal.

          -  Patients with any other chronic disease, for example: HIV, rheumatic diseases.

          -  Pregnant or positive pregnancy test.

          -  Women who are breastfeeding.

          -  Patients in another research project.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Gómez, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Gómez, Doctor</last_name>
      <phone>55133891</phone>
      <email>gomezperezfco@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paloma Almeda, Doctor</last_name>
      <phone>56554523</phone>
      <email>palomaalmeda@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco J Gómez, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. Erratum in: Diabetes Care. 2013 Feb;36(2):490.</citation>
    <PMID>22517736</PMID>
  </reference>
  <reference>
    <citation>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558.</citation>
    <PMID>9742977</PMID>
  </reference>
  <reference>
    <citation>Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011 Aug;32(15):1900-8. doi: 10.1093/eurheartj/ehr077. Epub 2011 Apr 6. Erratum in: Eur Heart J. 2012 May;33(10):1183.</citation>
    <PMID>21471135</PMID>
  </reference>
  <reference>
    <citation>Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005 Feb 8;111(5):583-90.</citation>
    <PMID>15699279</PMID>
  </reference>
  <reference>
    <citation>Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, Marre M, Porath A, Bhatt DL, Steg PG; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 Nov 22;170(21):1892-9. doi: 10.1001/archinternmed.2010.409.</citation>
    <PMID>21098347</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postprandial lipemia</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Metformin glycinate</keyword>
  <keyword>oxidized LDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

